Life is not back to normal, by any means, in any field of endeavor, and until the news pages are populated by stories of how those being cured of COVID-19 and exiting isolation outnumber those catching the disease and entering isolation, this strange state of affairs will predominate.
At least, late Monday, came word that a health-science company out of Los Angeles is making headway with its efforts at keeping the virus at bay, and appeared to be rewarded for those efforts by small-cap investors.
Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, announced in this first of four releases expected in the next 14 days, further details of its revolutionary Covid19-screening test GenViro!™.
“Our product,” read the news release, “introduced to the world only 14 days ago has entered its crucial development stage. We are awaiting release of blood samples from previously infected people in Daegu, Korea, so that we can complete testing and make a final report to the U.S. Food and Drug Administarion so that we may secure our Emergency Waiver.”
The stock price acknowledged the company’s work, climbing 1.46 cents, or 24.1%, to 7.51 cents, on volume verging on 15 million shares.
